

# A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer

Amit Joshi, Vijay M. Patil,

Vanita Noronha,

Joydeep Ghosh,

Atanu Bhattacharjee<sup>1</sup>,

Kumar Prabhash

Department of Medical Oncology,  
Tata Memorial Hospital, Mumbai,  
Maharashtra, <sup>1</sup>Division of Clinical  
Research and Biostatistics,  
Malabar Cancer Centre,  
Kerala, India

## Address for correspondence:

Dr. Kumar Prabhash,  
Department of Medical Oncology,  
Tata Memorial Hospital,  
Parel, Mumbai - 400 012,  
Maharashtra, India.  
E-mail: kumarprabhashtmh@gmail.com

## INTRODUCTION

Palliative chemotherapy in lung cancer has undergone major changes in the last decade.<sup>[1]</sup> Initially, palliative chemotherapy in lung cancer was decided on the basis of histology. Whether it was nonsmall-cell lung cancer (NSCLC) or small-cell lung cancer was sufficient to decide treatment. However, currently, not merely histological subclassifications (squamous cell carcinoma or adenocarcinoma) but also the mutation analysis determines the treatment. The discovery of driver mutations and development of small molecules targeting them has changed the way we treat NSCLC today.<sup>[1-3]</sup> Lung cancer treatment guidelines now recommend that at least epidermal growth factor receptor (EGFR) tyrosine kinase domain mutation analysis and ALK rearrangement must be done before starting treatment. Treatment recommendations are based on the results of these analysis.<sup>[4,5]</sup>

At our center, we follow these international guidelines. However, frequently we encounter a situation where either

## ABSTRACT

**Background:** Palliative chemotherapy + / - targeted therapy in accordance with mutation profile is the norm in nonsmall-cell lung cancer (NSCLC). The objective of this audit was to determine the proportion of patients and physicians, who are unwilling to wait for the mutation report and the reasons thereof. **Materials and Methods:** All newly diagnosed NSCLC patients, post biopsy, seen at our center between November 2014 and January 2015 were included. The relationship between patient and physician decision and objective factors was explored by Fisher's exact test. The factors considered were Eastern Cooperative Oncology Group performance status (ECOG PS), the presence of a cough, hemoptysis, fatigue, and breathlessness. The agreement between patients and physician decision was tested by contingency table. **Results:** Out of 168 patients, 57 were unwilling to wait for driver mutation report (33.9% 95% confidence interval [CI] 27.2-41.4%). The most common reason provided by patients was symptomatic status (23, 40.1%). No other objective factor except PS ( $P = 0.00$ ) was associated with patient's decision. In 56 patients (33.4% 95% CI 26.6-40.7%), physicians were unwilling to wait. Among the tested factors ECOG PS ( $P = 0.000$ ), breathlessness ( $P = 0.00$ ) and fatigue ( $P = 0.00$ ) were associated with the decision of not waiting for the report. The percentage corrected value of contingency between patients and physician decision was 78.74%. **Conclusion:** At present, in our setup, nearly one-third of our NSCLC patients opt for immediate chemotherapy treatment and are unwilling to wait for mutation analysis report. The major reasons for such attitude is poor symptom control and deteriorating general condition.

**Key words:** Acceptance, delay, epidermal growth factor receptor mutation analysis, nonsmall-cell lung cancer, willingness

the patient or the treating physician is unwilling to wait for the mutation analysis report. In an attempt to understand the reasons why either the patient or the physicians are unwilling to wait for the report we did an audit of all consecutive NSCLC patients who came to medical oncology lung cancer outpatient department. The objective of this audit was to determine the proportion of patients refusing to wait for the report and the reasons for the same.

## MATERIALS AND METHODS

### Patient selection

We maintain a lung cancer chemotherapy database of all newly registered NSCLC patients. All patients with lung referred for palliative chemotherapy are counseled about

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

**How to cite this article:** Joshi A, Patil VM, Noronha V, Ghosh J, Bhattacharjee A, Prabhash K. A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer. Indian J Med Paediatr Oncol 2016;37:74-8.

## Access this article online

### Quick Response Code:



Website:  
www.ijmpo.org

DOI:  
10.4103/0971-5851.180138

their diagnosis, stage, prognosis and treatment options. Then they are asked to wait till the availability of mutation analysis report (if applicable) and treatment is then started according to institutional local guidelines.

In this database from November 2014, we routinely started entering the patients and physicians willingness for waiting for treatment, till the availability of mutation report. In addition, we would also enter the reason for not waiting for the report.

The reasons for not waiting were coded as below:

1. Patients reason for not waiting:
  - a. Logistics: Patient does not have social support to stay in Mumbai
  - b. Symptomatic: Patient feels his/her symptoms are not adequately controlled by symptomatic medications and hence wants immediate chemotherapy
  - c. Poor general condition: Patient feels his/her general condition is poor, it may deteriorate further if he/she waits
  - d. Not willing for rebiopsy: Initially, biopsy has inadequate tissue but the patient is not willing for rebiopsy hence does not want to wait.
2. Physicians reason for not waiting:
  - a. Eastern Cooperative Oncology Group performance status (ECOG PS) 2-4: Physician feels that patients PS is poor, it may deteriorate further if he/she waits
  - b. Symptomatic: Physician feels that patients symptoms are not adequately controlled by symptomatic medications and hence recommends immediate chemotherapy
  - c. Emergency: Patient has Superior vena cava obstruction (SVCO) or spinal cord compression or other oncologic emergency that warrants immediate treatment
  - d. Others: Patient has already been started on chemotherapy outside our hospital.

All NSCLC cancer patients seen in lung cancer Medical Oncology Outpatient Department between November 2014 and January 2015 were selected for this analysis subjected to following criteria.

### Selection criteria

1. NSCLC patients referred for palliative chemotherapy
2. Biopsy available
3. Mutation analysis requested.

From the database, patients meeting these requirements were extracted. In addition, data regarding ECOG PS, stage, pathology, patient's decision regarding willingness to wait for mutation report and the reason for it and physicians willingness to wait for mutation report and the

reason for it were extracted. Electronic medical records and case file records were sought when any of the above data were found missing.

### Statistical analysis


R Studio version 3.1.2 (R: A Language and Environment for Statistical Computing, R Core Team, Vienna, Austria) was used for analysis. Descriptive statistics was performed. Categorical variables have been reported in the form of frequencies. The relationship between patients willingness to wait and factors was explored by Fisher's exact test for count data. The factors considered were ECOG PS (0-2 vs. 3-4), the presence of cough (yes, no), the presence of hemoptysis (yes, no), the presence of fatigue (yes, no), and the presence of breathlessness (yes, no). Similarly was the relationship between physicians willingness to wait and factors was explored. Binary logistic regression analysis was performed for multivariate analysis to identify independent factors influencing patients and physicians decision.

The agreement analysis between patients decision and physician decision was tested by software package library (VCD). It was kept in mind that the doctor's decision to some extent may be influenced by patient's decision and vice versa. As we were not sure about the assumption of decision independence between doctors and patients, we avoided the application of agreement analysis in this situation. Hence, the percentage correct value was estimated from the contingency table in this study. Decision tree used for contingency analysis is depicted in Figure 1.

## RESULTS

### Patient details

One hundred and sixty-eight patients were selected. One hundred and fifty-six (92.8%) patient had Stage IV disease whereas 11 patients (7.2%) had Stage III disease (not a candidate for radical treatment). The histology was



**Figure 1:** Decision tree used for contingency analysis

adenocarcinoma in 155 patients (92.2%). The ECOG PS was 0, 1, 2, 3, and 4 in 3 patients (1.8%), 85 patients (50.6%), 42 patients (25.0%), 36 patients (21.4%), and 2 patients (1.2%), respectively. Cough, hemoptysis, pain, breathlessness and fatigue were reported by 124 patients (73.8%), 22 patients (13.9%), 91 patients (54.2%), 106 patients (63.1%), and 88 patients (52.4%), respectively.

### Patients decision and reasons

Out of 168 patients, 111 patients (66.1%) were willing to wait for biopsy report while 57 (33.9%) were not. The reasons provided by patients for not waiting were symptomatic status in 23 patients (40.1%), a poor general condition in 19 patients (33.3%), the logistic issue in 14 (24.6%) and others in 01 (2.0%). Factors affecting patients decision are shown in Table 1. Only ECOG PS was associated with patients unwillingness to wait.

### Physicians decisions and reasons

Out of 168 patients, in 112 patients (66.6%) physicians were willing to wait for biopsy report while in 56 patients (33.4%) they were not. The reasons for not waiting were

symptomatic status in 28 patients (50.0%), poor PS in 22 patients (39.4%), emergency in 03 patients (SVCO-2, spinal cord compression-1), and others in 3 patients (05.3%). The reasons provided in others were old age in 2 patients and in 1 patient the chemotherapy had already been started. Factors affecting physicians decision are shown in Table 2. Though ECOG PS ( $P = 0.00$ ), breathlessness ( $P = 0.00$ ) and fatigue ( $P = 0.00$ ) were associated with physicians decision of not waiting for the report on univariate analysis only poor PS (0.00) was an independent factor influencing the decision identified on multivariate analysis.

### Concordance between physician and patient's decision

The  $2 \times 2$  table of the decision of patients and physician is shown in Table 3. The estimated percentage corrected value of contingency between patients and physician decision was 78.74%.

### DISCUSSION

The era of personalized medicine comes with a challenge. A major challenge faced by physicians is to convince

**Table 1: Different factors affecting patients decision making**

Variable	Variable subdivision	patient number in subdivision	Proportion of patients unwilling for waiting for report in subdivision (%)	P
ECOG PS	PS 0-2	130	36 (27.7)	0.00*
	PS 3-4	038	23 (60.5)	
Presence of cough	Yes	124	40 (32.3)	0.69
	No	044	17 (38.6)	
Presence of hemoptysis	Yes	022	09 (40.9)	0.70
	No	146	48 (32.9)	
Presence of pain	Yes	091	33 (36.3)	0.56
	No	077	24 (31.2)	
Presence of breathlessness	Yes	106	40 (37.7)	0.21
	No	062	17 (27.4)	
Presence of fatigue	Yes	088	34 (38.6)	0.19
	No	080	23 (28.8)	

\*Statistically significant value. ECOG – Eastern Cooperative Oncology Group; PS – Performance status

**Table 2: Different factors affecting physicians decision making**

Variable	Variable subdivision	Patient number in subdivision	Proportion of patients whose physicians unwilling for waiting for report in subdivision	P value on univariate analysis	P value on multivariate analysis
ECOG PS	PS 0-2	130	22 (16.9)	0.00*	0.00*
	PS 3-4	038	34 (89.5)		
Presence of cough	Yes	124	43 (34.6)	0.69	NA
	No	044	13 (29.5)		
Presence of hemoptysis	Yes	022	11 (50.0)	0.22	NA
	No	146	45 (30.8)		
Presence of pain	Yes	091	33 (36.3)	0.41	NA
	No	077	23 (29.9)		
Presence of breathlessness	Yes	106	47 (44.3)	0.00*	0.99
	No	062	09 (14.5)		
Presence of fatigue	Yes	088	42 (47.7)	0.00*	0.77
	No	080	14 (17.5)		

\*P value significant. NA – Only factors have a significant P value were included in multivariate analysis; ECOG – Eastern Cooperative Oncology Group; PS – Performance status

**Table 3: The concordance between patient and physician on willingness to wait for report**

Variables	Patient unwilling to wait	Patient willing to wait	Total
Physician unwilling to wait	40	16	56
Physician willing to wait	17	95	112
Total	57	111	Grand total=168

patients to perform investigations which make it possible to plan personalized treatment and in addition to patiently wait for such a report is available. Literature from the Western world clearly shows that patients are willing to do this. A study from North America by Cuffe *et al.* highlighted that 99% of patients in adjuvant setting and 97.4% in palliative setting respectively, are willing to undergo pharmacogenomic testing that would identify the cohort of patients who would benefit from therapy.<sup>[6]</sup> Though the majority of patients wanted to be a part of the decision-making process, 20% of patients lack the basic knowledge to do so.<sup>[6]</sup> A similar attitude toward pharmacogenetic testing was noted in the UK public by Finegold *et al.*<sup>[7]</sup> However, in our study, surprisingly one-third of patients even after being counseled regarding the benefit of EGFR mutation testing were not willing to wait for the report. EGFR and ALK testing is a part of routine protocol and hence, we recommend tissue biopsy in all NSCLC patients. Hence, the sample for mutation testing is acquired at the time of diagnostic confirmation itself. The report at our center is provided within 2 weeks which is at par with the international standards. In spite of this, we face opposition from many patients to wait for the report and hence we wanted to identify the factors responsible. Even the large studies done in Western countries have identified a small proportion of patients who are resistant to such testing but they fail to identify the reason behind this resistance.<sup>[7]</sup>

Our analysis determines that poor symptom control (40.1%) was the major reason for patient resistance to wait. Poor symptom control is associated with high distress and deterioration in performance status. The reason behind this may be that a dedicated palliative care clinic for lung cancer is not available for these patients. The other common reason which was provided by patients was a poor general condition. This seems to corroborate with poor performance status. The important question here is the reason for poor PS. If the reason were uncontrolled comorbidity or disease related immediately correctable (pleural effusion) cause then may be a repeat interview after corrective treatment may help the patient to change their decision. However, in case of poor PS because of other causes, waiting for report is unjustifiable. This is reflected in the fact that

poor PS patients and those with breathlessness were recommended the immediate start of therapy without awaiting the molecular report. The third common reason given by patients was logistics which was mainly because of lack of social support for staying in the city. This is a problem peculiar to our tertiary care referral center that draws patients from all parts of the country.

We have planned corrective steps toward improving patients compliance with the recommendation to wait for EGFR report. First is repeated counselling of patients who are unwilling to wait for the report. We are conducting group discussion meetings between patients, relatives, doctors and social workers so that in a more elaborate way, with the aid of audio-visual presentations the importance of mutation testing can be stressed. We thought that this step is necessary, as the Western population is nearly 100% literate but nearly 20% of Indian population is illiterate and hence the basic knowledge of decisions need to be explained in more simplified manner with visual aids.<sup>[8]</sup> Further efforts will be made for getting a dedicated palliative care expert for better management of symptoms preferably located near the medical oncology lung clinic. Facility would be provided for patients to access their reports online itself with a telephonic alert so that these patients staying far away can revisit our center or a center nearby for starting appropriate treatment. Finally, we are planning to expedite our lab efforts so that reports can be available within 1 week and develop liquid biopsy based molecular tests. We plan to repeat our analysis after 1 year of implementation of these measures to quantify the effect of our measures.

## CONCLUSION

At present, in our setup, nearly one-third of our NSCLC patients opt for immediate chemotherapy treatment and are unwilling to wait for mutation analysis report. The major reasons for such attitude are poor symptom control and deteriorating general condition.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

1. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3<sup>rd</sup> ed: American college of chest physicians evidence-based clinical practice guidelines. *Chest* 2013;143 5 Suppl:e142S-65S.
2. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: Recent developments. *Lancet* 2013;382:709-19.
3. Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. *J Clin Oncol* 2014;32:973-82.
4. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E; ESMO Guidelines Working Group. Metastatic non-small-cell

- lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012;23 Suppl 7:vii56-64.
5. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, *et al.* Non-small cell lung cancer, version 2.2013. *J Natl Compr Canc Netw* 2013;11:645-53.
  6. Cuffe S, Hon H, Qiu X, Tobros K, Wong CK, De Souza B, *et al.* Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. *Pharmacogenet Genomics* 2014;24:348-55.
  7. Finegold P, Mathieson K, Holmes L, Boon M, Cottle M, Donnai D, *et al.* Is the UK public ready for genetic medicine? *Pers Med* 2008;5:65-76.
  8. ORGI: Census of India Website: Office of the Registrar General & Census Commissioner, India. Website: <http://censusindia.gov.in/> [Last accessed on 2015 Apr].

### Author Help: Online submission of the manuscripts

Articles can be submitted online from <http://www.journalonweb.com>. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) **First Page File:**

Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) **Article File:**

The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 1 MB. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) **Images:**

Submit good quality color images. Each image should be less than 4096 kb (4 MB) in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) **Legends:**

Legends for the figures/images should be included at the end of the article file.